Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-Gastric/Gastroesophageal Junction Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT02205047
What this trial is testing

Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Malignant Neoplasm of StomachMalignant Neoplasm of Cardio-esophageal Junction of StomachEpidermal Growth Factor Receptor (EGFR) Protein Overexpression
European Organisation for Research and Treatment of Cancer - EORTC 172
Early research (Phase 1)Study completedNCT03752398
What this trial is testing

XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)

Who this might be right for
Melanoma (Excluding Uveal Melanoma)Cervical CarcinomaPancreatic Carcinoma+13 more
Xencor, Inc. 198
Large-scale testing (Phase 3)Looking for participantsNCT06221748
What this trial is testing

DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy

Who this might be right for
Gastric CancerGastroesophageal Junction Adenocarcinoma
RemeGen Co., Ltd. 90
Early research (Phase 1)Active Not RecruitingNCT05382364
What this trial is testing

Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)

Who this might be right for
Metastatic HER2+ Advanced Breast CancerBreast NeoplasmsGastric or Gastroesophageal Junction Adenocarcinoma (GEC)+1 more
Pfizer 25
Testing effectiveness (Phase 2)Looking for participantsNCT06650332
What this trial is testing

Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients

Who this might be right for
Metastatic HER2 Positive Gastroesophageal Junction Cancer
Zhejiang Cancer Hospital 90
Early research (Phase 1)Looking for participantsNCT06999187
What this trial is testing

DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

Who this might be right for
Triple Negative Breast CancerHER2-negative Breast CancerNon Small Cell Lung Cancer+9 more
Dren Bio 96
Testing effectiveness (Phase 2)Study completedNCT04989816
What this trial is testing

Study of T-DXd Monotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma Who Have Received 2 or More Prior Regimens

Who this might be right for
Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
AstraZeneca 95
Testing effectiveness (Phase 2)Study completedNCT07529613
What this trial is testing

Trastuzumab Deruxtecan Plus Nivolumab Plus Capecitabine Plus Oxaliplatin for HER2 Low Gastric and Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
National Cancer Center Hospital East 30
Testing effectiveness (Phase 2)Looking for participantsNCT06023758
What this trial is testing

Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC

Who this might be right for
HER2-positive Locally Advanced Resectable Gastric Cancer
Peking University 18
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06881017
What this trial is testing

Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping

Who this might be right for
Gastric CancerHER2 + Gastric CancerCLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction+1 more
China Medical University, China 140
Testing effectiveness (Phase 2)Looking for participantsNCT06330064
What this trial is testing

Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

Who this might be right for
Recurrent or Metastatic Solid Tumors
Daiichi Sankyo 680
Large-scale testing (Phase 3)Study completedNCT03615326
What this trial is testing

Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

Who this might be right for
Gastric NeoplasmsGastroesophageal Junction Adenocarcinoma
Merck Sharp & Dohme LLC 738
Testing effectiveness (Phase 2)Looking for participantsNCT06750185
What this trial is testing

Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumor
BioNTech SE 248
Testing effectiveness (Phase 2)UnknownNCT03588533
What this trial is testing

Herzuma-capecitabine/Cisplatin for Gastric Cancer

Who this might be right for
HER-2 Positive Gastric CancerMetastatic Cancer
Sung Yong Oh 50
Early research (Phase 1)Looking for participantsNCT07660055
What this trial is testing

Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors

Who this might be right for
Breast CancerNon-small Cell Lung Cancer (NSCLC)Gastric/Gastroesophageal Junction (GEJ) Cancer+1 more
Novartis Pharmaceuticals 156
Testing effectiveness (Phase 2)UnknownNCT01359397
What this trial is testing

Docetaxel, Oxaliplatin, Capecitabine, Bevacizumab and Trastuzumab in Patients With Locally Advanced or Metastatic Gastric Cancer

Who this might be right for
Metastatic Gastric CancerAdenocarcinoma of the Gastro-oesophageal Junction
The Netherlands Cancer Institute
Early research (Phase 1)Active Not RecruitingNCT04704661
What this trial is testing

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Who this might be right for
Advanced Breast CarcinomaAdvanced Colon CarcinomaAdvanced Colorectal Carcinoma+37 more
National Cancer Institute (NCI) 51
Large-scale testing (Phase 3)Active Not RecruitingNCT05144854
What this trial is testing

Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)

Who this might be right for
Gastric Cancer
Ono Pharmaceutical Co., Ltd. 626
Large-scale testing (Phase 3)Looking for participantsNCT05918094
What this trial is testing

Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric Cancer
Sun Yat-sen University 540
Not applicableStudy completedNCT02305043
What this trial is testing

Identification of Biomarkers for Prediction of Response or Resistance Against Target Therapy in Gastric Cancer

Who this might be right for
Esophageal NeoplasmsStomach Neoplasms
University of Leipzig 549
Next Page